A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes

被引：0
|
作者：
de Castro, C. [1 ]
Adams, D. [1 ]
Rizzieri, D. [1 ]
Moore, J. [1 ]
Gockerman, J. [1 ]
Diehl, L. [1 ]
Horwitz, M. [1 ]
Edmonds, E. [1 ]
Warzecho, J. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC 27706 USA
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70210-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S134 / S134
页数：1
相关论文
共 50 条
  • [31] Arsenic trioxide (Trisenox®) with/without thalidomide in patients with myelodysplastic syndromes (MDS) produces hematologic improvement (HI).
    Raza, A
    Lisak, L
    Billmeier, J
    Akbar, S
    Washeed, K
    Mumtaz, M
    Reddy, P
    Galili, N
    BLOOD, 2004, 104 (11) : 261B - 262B
  • [32] Clinical Experience of Decitabine in Elderly Patients with Myelodysplastic Syndromes (MDS)
    Geils, George F., Jr.
    BLOOD, 2009, 114 (22) : 1092 - 1092
  • [33] PATIENTS' PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
    Zeidan, A.
    Perepezko, K.
    Salimi, T.
    Washington, T.
    Epstein, R.
    LEUKEMIA RESEARCH, 2023, 128
  • [34] Decitabine in myelodysplastic syndromes: profile report
    Drugs & Therapy Perspectives, 2006, 22 (11) : 6 - 7
  • [35] Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients
    Zheng, Wen-Li
    Zhang, Guang-Sen
    Xu, Yun-Xiao
    Shen, Jian-Kai
    Dai, Chong-Wen
    Pei, Min-Fei
    LEUKEMIA RESEARCH, 2008, 32 (02) : 251 - 254
  • [36] Trisenox® (arsenic trioxide, ATO) in patients (pts) with myelodysplastic syndromes (MDS):: Preliminary findings in a phase II clinical study.
    List, AF
    Schiller, GJ
    Mason, J
    Douer, D
    Paradise, C
    BLOOD, 2002, 100 (11) : 790A - 790A
  • [37] A phase II pilot study of sorafenib in patients with myelodysplastic syndromes
    de Castro, C.
    Adams, D.
    Rizzieri, D.
    Moore, J.
    Gockerman, J.
    Diehl, L.
    Horwitz, M.
    Edmonds, E.
    Warzecho, J.
    LEUKEMIA RESEARCH, 2009, 33 : S137 - S137
  • [38] Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study
    Xiao, Zhijian
    Xu, Zefeng
    Zhang, Yue
    Qin, Tiejun
    Zhang, Hongli
    Fang, Liwei
    LEUKEMIA RESEARCH, 2011, 35 (01) : 61 - 65
  • [39] Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes
    Dvirnyk, V. N.
    Kokhno, A. V.
    Glasko, E. N.
    Gemdjian, E. G.
    Dyagileva, O. A.
    Platonova, T. L.
    Parovichnikova, E. N.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (07) : 65 - 71
  • [40] Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
    Zeidan, Amer M.
    Perepezko, Kate
    Salimi, Tehseen
    Washington, Terri
    Epstein, Robert S.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
12345